Two studies presented at the recent NKF Spring Clinical Meetings provide more evidence of a trend toward decreasing use of ESAs and decreasing hemoglobin levels.
Having just returned from the always-stimulating European Association of Urology annual congress, I'd like to share a few impressions.
Almost half a million Americans depend on chronic dialysis therapy to survive.
Physicians are more often defined by their ability to diagnose, treat, and research a disease than their willingness to manage its spectrum of risk.
How often have you met for business in a Starbucks, Coffee Bean, or any other coffee shop?
Kidney Week 2012, held in San Diego, is now history and as usual I like to reflect on the world's biggest and most prestigious meeting for kidney specialists.
Although data suggest that cancer rates are also higher in obese patients, the associations are largely based on observational/population studies.
President Obama and Mitt Romney square off on American health reform in the New England Journal of Medicine.
In recent trips to India, China, Brazil, and other countries, I was intrigued by large numbers of patients with end-stage renal disease who underwent hemodialysis (HD) less frequently than three times a week.
In the past few years, urologists have seen some significant developments related to the treatment of metastatic castration-resistant prostate cancer (CRPC).
Unfortunately, in the past few years, very few studies have looked at issues regarding gender and CKD, and of most concern, looking at response to therapy.
More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
As practicing clinicians in the United States, we generally feel privileged, with access to a highly developed and pioneering medical care system along with an advanced and cutting-edge technology in the world's largest economy.
The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.
An impressive story of a dialysis survivor who watched his daughters grow and getting married, and had the joy of knowing several grandchildren.
How often do you face with the unpleasant task of waking a sleeping patient during your busy rounds? It happens frequently to many clinicians during their inpatient rounds in the hospital.
The start of 2012 is a good time to look back on the previous year to see the current state of nephrology. What have been the important findings that occurred in the past year, and what do we have to look forward to in the year ahead?
For the ninth straight year, I came away from Kidney Week (formerly Renal Week), the annual scientific meeting of the American Society of Nephrology, feeling badly that Renal & Urology News can only report on a fraction of the thousands of studies presented at the meeting.
According to current estimates, kidney stones will develop in one in 10 people during their lifetime. This translates into nearly 30 million people in the United States. Clearly, prevention is paramount when dealing with kidney stones.
Individuals, businesses and nations grapple with how to measure success. Are similar productivity measures warranted in medicine?
Physicians are indeed spending less face time with patients, according to studies and to what doctors have told me in conversation. One consequence of this could be less time to educate patients about their illness.
Many obese dialysis patients are asked to lose weight to qualify for kidney transplantation. If such usual weight reduction programs as dieting or anti-appetite medications do not work, some patients will be introduced to more aggressive interventions such as bariatric surgery.
Traditional nephrology training makes us believe that it is good practice to start maintenance dialysis therapy sooner rather than later. Nevertheless, recent data indicate that we may encounter yet another "old-practice-was-wrong" paradigm shift.
Incidentally detected renal tumors are increasingly diagnosed in patients with chronic kidney disease.
Nephrologists should rethink the screening level and offer a more conservative and meaningful cutoff level, such as an eGFR of 45.
Practicing nephrologists are frequently consulted to evaluate acute kidney injury (AKI) as inpatient cases.
The role of PSA as a cancer screening tool has recently been evaluated by several large high profile studies with varying interpretations of the data. Regardless of where one stands on the debate, among the clinical dilemmas of PSA-based screening is the negative biopsy conundrum where the reality remains that the best one can offer is, "Good news Mr. Smith, I don't think you have prostate cancer."
The advantages of this emerging specialty are clear to those involved in vascular access care, but some potential downsides must be considered.
Many Americans harbor fears about the Canadian health care system, and I would like to clear up some misconceptions.
The pending legislation on health care reform can be polarizing, but the motivation supporting it is not.